Add Yahoo as a preferred source to see more of our stories on Google. Chances are, you may know a family living with food allergies. Food allergies are more prevalent than many realize, particularly ...

Please provide your email address to receive an email when new articles are posted on . Omlyclo is approved to treat the same four conditions as omalizumab. There are now three doses/solutions of ...

A medication used to treat asthma can now be used to help people with food allergies avoid severe reactions, the U.S. Food and Drug Administration said Friday. Xolair, the brand name for the drug ...

On December 3, 2025, Celltrion announced that the FDA has approved a new dose of OMLYCLO (omalizumab-igec), the first and only biosimilar designated as interchangeable with Genentech and Novartis’s ...

BRIDGEWATER, N.J., Sept. 26, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (AMRX) (“Amneal” or the “Company”) today announced the submission of a Biologics License Application (BLA) to the U.S ...

Patients who take omalizumab prior to starting oral immunotherapy (OIT) may skip much of the latter treatment’s onerous dose escalation process, according to a new study presented at the American ...

A string of FDA approvals and late-stage clinical trials has expanded the toolkit for treating seasonal and environmental allergies, giving patients new ways to manage symptoms and, in some cases, ...

LONDON and REYKJAVIK, Iceland, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

In an observational cohort study of patients with chronic spontaneous urticaria, fast responders to omalizumab (≤ 1 month) had the longest drug survival (median, 3.9 years) and required lower ...